Holen Sie sich die Stockscreener-App
1.13
4.24%
-0.05
Schlusskurs vom Vortag:
$1.18
Offen:
$1.15
24-Stunden-Volumen:
43,834
Relative Volume:
0.41
Marktkapitalisierung:
$10.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.57M
KGV:
-0.1794
EPS:
-6.3
Netto-Cashflow:
$-38.56M
1W Leistung:
-23.65%
1M Leistung:
-27.56%
6M Leistung:
-56.87%
1J Leistung:
-74.43%
1-Tages-Spanne:
$1.00
$1.1562
1-Wochen-Bereich:
$1.00
$1.52
52-Wochen-Spanne:
$1.00
$5.01
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Vergleichen Sie SABS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
1.13 | 10.43M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
FY2025 Earnings Forecast for SABS Issued By Chardan Capital - Defense World
HC Wainwright Brokers Boost Earnings Estimates for SABS - Defense World
SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital - Defense World
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan - TipRanks
Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating - TipRanks
SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire
SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials - Stock Titan
SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 - TipRanks
SAB Biotherapeutics, Inc. SEC 10-K Report - TradingView
Financial Contrast: SAB Biotherapeutics (NASDAQ:SABS) versus Kiromic BioPharma (NASDAQ:KRBP) - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36 - MSN
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 6.7% – Here’s Why - Defense World
SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142 - News-Medical.Net
Q1 Earnings Estimate for SABS Issued By HC Wainwright - Defense World
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
Diabetes Treatment Pioneer SAB BIO Sets Stage for Major Investor Presentations - StockTitan
Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
SAB Biotherapeutics To Advance SAB-142 Into Phase 2b Trials After Positive Phase 1 Results - Nasdaq
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Marketscreener.com
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
3 Promising US Penny Stocks With At Least $20M Market Cap - simplywall.st
SAB Biotherapeutics (SABS) Stock Price, News & Analysis - MarketBeat
SAB BIO Announces R&D Webinar Event to Review Phase 1 - GlobeNewswire
SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 60.5% in December - Defense World
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
SABS FY2024 EPS Reduced by Brookline Capital Management - Defense World
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Yahoo Finance
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - Yahoo Finance
Ex-Wells Fargo investment banker named CFO of pharma company - The Business Journals
SAb Biotherapeutics, Inc. : Quotes, Address, Contact - News-Medical
MarketBeat June market recap - SiouxFalls.Business
SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewswire
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):